NCT00650663View on ClinicalTrials.gov

Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)

PHASE4CompletedINTERVENTIONAL

Enrollment

247

Participants

Timeline

Start Date

October 1, 2003

Primary Completion Date

September 1, 2004

Study Completion Date

September 1, 2004

Conditions

HypercholesterolemiaAtherosclerosis

Interventions

DRUG

Ezetimibe + Simvastatin

oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks

DRUG

Simvastatin

oral tablet; simvastatin 20 mg once daily for 12 weeks

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Organon and Co

INDUSTRY

NCT00650663 - Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377) | Biotech Hunter | Biotech Hunter